Aaron Brewer
Optometrist · Stilwell, OKNPI 1033306709
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 307 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 26 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,179 and has fallen 51.7% since, to $1,052 in 2025. Among optometrist clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $33.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$2K
- Alcon$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- AbbVie$1K
- Glaukos Corporation$796
- Coopervision Inc.$546
- plus $2K from 20 others
What the payments were for
- Consulting fees$6006%
- Food & beverage$9,53194%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 67 | $2,081 |
| Alcon | 67 | $1,842 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 43 | $1,339 |
| AbbVie(2 entities) | 41 | $1,283 |
| Glaukos Corporation | 7 | $796 |
| Coopervision Inc. | 21 | $546 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $256 |
| Sun Pharmaceutical Industries Inc. | 4 | $243 |
| Tarsus Pharmaceuticals, Inc. | 5 | $195 |
| Dompe US, Inc. | 4 | $194 |
| Lombart Brothers, Inc. | 4 | $190 |
| LKC Technologies, Inc. | 3 | $181 |
| Oyster Point Pharma, Inc. | 7 | $176 |
| Eyevance Pharmaceuticals LLC | 5 | $165 |
| Sight Sciences, Inc. | 3 | $144 |
| Novartis | 6 | $119 |
| Kala Pharmaceuticals, Inc. | 4 | $85 |
| Astellas Pharma US Inc | 3 | $69 |
| Staar Surgical Company | 1 | $48 |
| Shire North American Group Inc | 3 | $48 |
| Aerie Pharmaceuticals, Inc. | 2 | $41 |
| Carl Zeiss Meditec USA, Inc. | 1 | $27 |
| Harrow Eye, LLC | 1 | $24 |
| Maculogix, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Lumenis, Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TOTAL30$259
- DURYSTA$252
- INFUSE$226
- XEN GLAUCOMA TREATMENT SYSTEM$148
- OPD-III$144
- Zerviate$133
- Tecnis Simplicity$131
- Tecnis IOL$125
- Oxervate$125
- XDEMVY$123
- VUITY$115
- LUMIGAN$113
- CEQUA$112
- LOTEMAX SM$111
- TearCare SmartLid$106
- TEARCARE(TM) (2.2) SYSTEM KIT$106
How this compares
$10,150 in reported general payments places this provider in the 95th percentile of 714 optometrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $52,537 |
| MieboPerfluorohexyloctane/Pf | 25 | $18,947 |
| LumiganBimatoprost | 11 | $8,205 |
| Loteprednol Etabonate | 19 | $2,468 |
| Fluorometholone | 36 | $2,377 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 19 | $874 |
| Latanoprost | 40 | $350 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 24 | $228 |
| Timolol Maleate | 14 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $1,283 | $60,74350 claims |
| Bausch & Lomb Americas Inc.Miebo | $2,081 | $18,94725 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $1,339 | $2,46819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 714 optometrist providers in Oklahoma.
Other optometrist in Stilwell
- Selina McGeeEdmond$1.1M
- Nathan LighthizerTahlequah$1M
- Lindsey BullTulsa$218K
- Jeff MillerTahlequah$67K
- Joseph PhillipsOklahoma City$52K
- Wesley DerosierTulsa$48K
- Charles WhittleTahlequah$28K
- Latricia PackTahlequah$25K
- Scott ForesterOklahoma City$17K
- Cindy ShanTahlequah$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.